Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non‐small cell lung cancer

BACKGROUND: Biomarker assessments for nivolumab monotherapy efficacy in previously treated patients with non‐small cell lung cancer (NSCLC) remain unclear. We evaluated whether body mass index (BMI) and Glasgow prognostic score (GPS) are useful for assessing the efficacy of nivolumab alone as a seco...

Descripción completa

Detalles Bibliográficos
Autores principales: Imai, Hisao, Naito, Erika, Yamaguchi, Ou, Hashimoto, Kosuke, Iemura, Hidetoshi, Miura, Yu, Shiono, Ayako, Mouri, Atsuto, Kaira, Kyoichi, Kobayashi, Kunihiko, Kagamu, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108038/
https://www.ncbi.nlm.nih.gov/pubmed/35394119
http://dx.doi.org/10.1111/1759-7714.14417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108038/
https://www.ncbi.nlm.nih.gov/pubmed/35394119
http://dx.doi.org/10.1111/1759-7714.14417

Ejemplares similares